Hispanic Heritage Month and Psychedelics
Celebrate National Hispanic Heritage Month by expressing gratitude for Hispanic and Latinx visionaries, researchers, community members, and others who have expanded awareness about psychedelics. Taking …
Participant Safety in Psychedelic Therapy
All stakeholders at the Multidisciplinary Association for Psychedelic Studies (MAPS) and MAPS Public Benefit Corporation (MAPS PBC) are committed to providing quality and comprehensive training and supervision …
MAPS PBC Publishes Results of Successful Confirmatory Phase 3 Trial of MDMA-Assisted Therapy for PTSD
FOR IMMEDIATE RELEASE: September 14, 2023 Results of the second, confirmatory Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder, MAPP2, have been published in Nature Medicine. MAPP2 …
MAPS Launches Online Video Sessions from Psychedelic Science 2023 with The Virtual Trip
The Multidisciplinary Association for Psychedelic Studies (MAPS) has begun publishing a collection of content from the highly acclaimed Psychedelic Science 2023 conference. PS2023: The Virtual Trip brings …
FDA Division of Pulmonology, Allergy, and Critical Care Provides Additional Guidance on Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
On August 11, the FDA Division of Pulmonology, Allergy, and Critical Care (DPACC) sent MAPS additional guidance on the safety of smoking in naïve subjects in MJP2. The FDA’s correspondence was a …
FDA Sends the Official Minutes of Type A Meeting for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
On July 12, 2023, the FDA Division of Psychiatry sent MAPS the official minutes of our Type A meeting on June 15, 2023. The Type A meeting focused on the issues the FDA cited in its Clinical Hold on the …
MAPS Receives $5 Million Grant from the Steven & Alexandra Cohen Foundation
MAPS and the Steven & Alexandra Cohen Foundation Partner to Support the Development of Psychedelic-Assisted Therapies FOR IMMEDIATE RELEASE: June 22, 2023 TheMultidisciplinary Association for Psychedelic …
MAPS-Sponsored Global Psychedelic Survey Gathers Data for a Crucial View into Psychedelic Use
FOR IMMEDIATE RELEASE: May 22, 2023 The Multidisciplinary Association for Psychedelic Studies (MAPS) announced the launch of the Global Psychedelic Survey. Co-sponsored by MAPS, SABI Mind, Mind Medicine …
FDA Grants In-Person Type A Meeting Request to Discuss Clinical Hold on Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
After reviewing MAPS’ Type A Meeting Request and Briefing submitted on April 28, the FDA granted MAPS’ meeting request. MAPS and the FDA will have a face-to-face formal meeting to discuss the …
MAPS Requests FDA for a Type A Meeting to Discuss Clinical Hold for the Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)
On April 28, 2023, MAPS requested the FDA for a Type A meeting to discuss the clinical hold issues for Study MJP2 in order to overcome the clinical hold deficiencies. This meeting request is in response …
Celebrating 37 Years of Psychedelic Science🎉
“You and I are the force for transformation in the world. We are the consciousness that will define the nature of the reality we are moving into.” Ram Dass Today is MAPS’ 37th anniversary! Almost …
STATEMENT: MAPS-Funded Phase 3 Research Reports Results from Long-Term Observational Follow-Up Study on MDMA-Assisted Therapy for PTSD
FOR IMMEDIATE RELEASE: April 5, 2023 MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), announced preliminary findings …